The NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection (to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org) provide a set of sequential recommendations detailing a screening and subsequent workup strategy for maximizing the detection of prostate cancer in an early, organ-confined state and attempting to minimize unnecessary procedures. These guidelines were developed for men who have elected to participate in prostate cancer screening; they are not meant to address the controversy regarding population screening.

Overview

Prostate cancer is the most commonly diagnosed...
cancer and the second leading cause of cancer death in American men. More than 192,000 men will be diagnosed with prostate cancer in 2009, and an estimated 27,360 men will die of this disease.¹

During the same period, nearly 20 million men in the United States will be confronted with important decisions regarding early detection for prostate cancer. Men in the United States have an approximately 1 in 6 chance of eventually being diagnosed with this malignancy and about 1 in 30 chance of eventually dying of it.² African-American men and men with a first-degree relative with prostate cancer (especially cancer found at a younger age) have a higher risk for developing prostate cancer.²⁻⁴ In a recent study of 26,111 men, the baseline prostate-specific antigen (PSA) value was found to be a stronger predictive factor than a positive family history or being of African-American heritage.⁵ Men who undergo regular PSA tests have a higher chance of undergoing a prostate biopsy and finding out they have prostate cancer than those who do not undergo these tests. However, familial prostate cancers generally follow a more aggressive course, with higher grade and stage at diagnosis and increased risk for death from the disease.⁶

**Controversies on PSA Testing**

The decision about whether to pursue early detection of prostate cancer is complex. When, who, and how to test remain major topics of debate among panelists. In brief, the dilemma is that because most

---

**NCCN Prostate Cancer Early Detection Panel Members**

Mark H. Kawachi, MD/Chair
City of Hope Comprehensive Cancer Center

Robert R. Bahnson, MD
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

Michael Barry, MD
Massachusetts General Hospital Cancer Center

J. Erik Busby, MD
University of Alabama at Birmingham Comprehensive Cancer Center

Peter R. Carroll, MD
UCSF Helen Diller Family Comprehensive Cancer Center

H. Ballentine Carter, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

William J. Catalona, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Michael S. Cookson, MD
Vanderbilt-Ingram Cancer Center

Jonathan I. Epstein, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Ruth B. Etzioni, PhD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Veda N. Giril, MD
Fox Chase Cancer Center

George P. Hemstreet III, MD, PhD
UNMC Eppley Cancer Center at The Nebraska Medical Center

Richard J. Howe, PhD
Consultant

Paul H. Lange, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Hans Lilja, MD, PhD
Memorial Sloan-Kettering Cancer Center

Kevin R. Loughlin, MD
Dana Farber/Brigham and Women’s Cancer Center

James Mohler, MD
Roswell Park Cancer Institute

Judd Moul, MD
Duke Comprehensive Cancer Center

Robert B. Nadler, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Stephen G. Patterson, MD
H. Lee Moffitt Cancer Center & Research Institute

Joseph C. Presti, MD
Stanford Comprehensive Cancer Center

Antoinette M. Stroup, PhD
Huntsman Cancer Institute at the University of Utah

Robert Wake, MD
St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute

John T. Wei, MD, MS
University of Michigan Comprehensive Cancer Center

**KEY:**

*Writing Committee Member

Specialties: ωUrology; ♂Internal Medicine; ≠Pathology; ♦Biostatistician; †Medical Oncology; ¥Patient Advocacy; ¶Surgery/Surgical Oncology; &Epidemiology
INTRODUCTION

It is neither the intent nor the suggestion of the panel that all men diagnosed with prostate cancer require treatment. It is inherent that as we maximize the detection of early prostate cancer we will increase the detection of both non-aggressive (slow growing) and aggressive (faster growing) prostate cancers. The challenge is to identify the biology of the cancer that is detected and thus identify cancers that, if treated effectively, will result in a significant decrease in morbidity and mortality. This variability in prostate tumor behavior is unlike any other cancer, and consequently causes major concern regarding the problem of over-treatment having potentially significant adverse implications on quality of life issues (e.g., urinary, bowel, and erectile dysfunction). The natural history of prostate cancer is that it will progress over time, but the unanswerable question is over what period of time. These guidelines do not address the treatment of prostate cancer. The guidelines are specifically for men opting to participate in an early detection program (after receiving the appropriate counseling on the pros and cons). It is the majority opinion of the Prostate Cancer Early Detection Panel members that there is a growing population of men currently being diagnosed with prostate cancer who can, and should, be monitored for their disease as presented in the NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org). The guidelines for a baseline prostate-specific antigen (PSA) level and lowering the PSA thresholds for biopsy were recommended by most panel members, but a consensus was not reached.

The guidelines are continuously in a state of evolution and the panel will incorporate changes based on new evidence and expert opinion and provide a rating of consensus with respect to each recommendation. See Suggested “talking points” to cover in a discussion with a potential screenee about the pros and cons of PSA testing (pages 250 and 251).
Prostate Cancer Early Detection Version 2:2010

### Baseline Evaluation
- **H&P** including:
  - Family history
  - Medications
  - History of prostate disease and screening, including prior PSA and/or isoforms, exams, and biopsies
  - PSA velocity, if available

### Risk Assessment
- Start risk and benefit discussion and
- Offer baseline DRE and PSA at age 40 (category 2B)

### Screening Evaluation
- **PSA ≥ 1.0 ng/mL**
  - **or African American or Family history**
  - **Annual follow-up (category 2B):**
    - DRE
    - PSA

- **PSA < 1.0 ng/mL**
  - **Repeat at age 45**

- **PSA > 1.0 ng/mL**
  - **Offer regular screening at age 50**

### Follow-Up
- **PSA ≤ 1.0 ng/mL**
  - **Repeat at age 45**
  - If PSA ≤ 1.0 offer regular screening at age 50

- **PSA > 1.0 ng/mL**
  - **Annual follow-up (category 2B):**
    - DRE
    - PSA

**See Diagnostic Evaluation (page 244)**

---

**Screening in men older than 75 years should be considered individually.**

**PSA velocity:** For men with PSA < 4 ng/mL, data suggest that a PSA velocity of ≥ 0.35 ng/mL per year is suspicious for the presence of cancer (Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521-1527); for men with PSA 4-10 ng/mL, a PSA velocity of ≥ 0.75 ng/mL per year is suspicious for cancer. PSA velocity in men with PSA > 10 ng/mL has not been determined useful. Measurement should be made on at least 3 consecutive specimens drawn over at least an 18- to 24-month interval. There is variability; longer time periods increase reliability but, as calculation of PSA velocity over longer prior time intervals usually decreases the PSA velocity estimate, they might decrease predictive power. It is also important to remember that biologic variability and/or prostatitis may be confounding factors in determining PSA velocity; therefore, antibiotic therapy and repeated PSA measurements may be considered to minimize these sources of confusion.

**The PSA value of 1.0 ng/mL selects for the upper range of PSA values for men aged 40-49 years.**

**No evidence in the literature supports the follow-up recommendations listed; they represent the consensus-based opinions of the panel members based upon their clinical experience.**

**Less-frequent PSA/DRE follow-up in the older patient may be appropriate based on their individual risk stratification.**
Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise noted.

© Journal of the National Comprehensive Cancer Network | Volume 8 Number 2 | February 2010
**Prostate Cancer Early Detection Version 2:2010**

**DIAGNOSTIC EVALUATION**

**DRE**
- Offer total PSA
  - See Screening Results and Follow-up (page 246)

**SCREENING RESULTS**
- DRE negative
  - PSA performed
    - In patients using finasteride or dutasteride, failure to have a substantial decrease (approximately 50%) in PSA or an increase while on medication can be associated with an increased risk for prostate cancer.
    - See NCCN Prostate Cancer Guidelines

**FOLLOW-UP**

- **DRE positive Regardless of PSA result:**
  - findings from TRUS-guided biopsy (see page 249)

- **Atypia, suspicious for cancer or High-grade PIN**
  - See Follow-up for TRUS-guided Biopsy (page 249)

- **Benign**
  - See Screening Results (page 246)

---

*To view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org

PSA
- **Ejaculation:**
  - Results are more reliable if patient has abstained from ejaculation for 48 h. If this condition is not met, repeat after 48 h abstention, if the original sample was marginally elevated.
- **Medicines that affect PSA:**
  - Finasteride
  - Androgen receptor blockers
  - Dutasteride

hIn patients using finasteride or dutasteride, failure to have a substantial decrease (approximately 50%) in PSA or an increase while on medication can be associated with an increased risk for prostate cancer.
SCREENING RESULTS

DRE negative
PSA performed

- PSA ≤ 2.5 ng/mL and PSA velocity < 0.35 ng/mL per year if available
  - Annual DRE and PSA

- PSA 2.6-4 ng/mL or PSA velocity ≥ 0.35 ng/mL per year when PSA ≤ 2.5 ng/mL
  - Consider biopsy
  - TRUS-guided biopsy performed (see page 249)

- PSA 4-10 ng/mL
  - See PSA 4 to 10 ng/mL (facing page)

- PSA > 10 ng/mL
  - See PSA > 10 ng/mL (page 248)

FOLLOW-UP

- PSA velocity < 0.35 ng/mL per year
  - Continue follow-up

- PSA velocity ≥ 0.35 ng/mL per year
  - Consider initial TRUS-guided biopsy (see page 249)

- Cancer
  - See NCCN Prostate Cancer Guidelines

- Atypia, suspicious for cancer or high-grade PIN
  - See Follow-up for TRUS-guided Biopsy (page 249)

- Benign
  - 6-12 mo follow-up with DRE
  - Consider percent free PSA

Use of free PSA in considering initial biopsy:
- ≤ 10% Biopsy
- > 10%, ≤ 25% Consider biopsy
- > 25% Consider deferring biopsy

*To view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org.

---

**PSA velocity:** For men with PSA < 4 ng/mL, data suggest that a PSA velocity of ≥ 0.35 ng/mL per year is suspicious for the presence of cancer (Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521-1527); for men with PSA 4-10 ng/mL, a PSA velocity of ≥ 0.75 ng/mL per year is suspicious for cancer. PSA velocity in men with PSA > 10 ng/mL has not been determined useful. Measurement should be made on at least 3 consecutive specimens drawn over at least an 18- to 24-month interval. There is variability. Longer time periods increase reliability but, as calculation of PSA velocity over longer prior time intervals usually decreases the PSA velocity estimate, they might decrease predictive power. It is also important to remember that biologic variability and/or prostatitis may be confounding factors in determining PSA velocity; therefore, antibiotic therapy and repeated PSA measurements may be considered to minimize these sources of confusion.

**Factors to consider:** age (men > 75 y should be considered individually), comorbid conditions, percent free PSA, prostate exam/size, strength of family history, African American.

**Free PSA** is not generally used in deciding whether or not to perform an initial biopsy. However, in selected circumstances, it may be considered employing the following recommendations: > 25%, no biopsy; ≤ 10% biopsy; > 10% and ≤ 25% indeterminate, consider biopsy.
**Factors to consider:** age (men > 75 y should be considered individually), comorbid conditions, percent free PSA, prostate exam/size, strength of family history, African American.

**PSA velocity:** For men with PSA < 4 ng/mL, data suggest that a PSA velocity of ≥ 0.35 ng/mL per year is suspicious for the presence of cancer (Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521-1527); for men with PSA 4-10 ng/mL, a PSA velocity of ≥ 0.75 ng/mL per year is suspicious for cancer. PSA velocity in men with PSA > 10 ng/mL has not been determined useful. Measurement should be made on at least 3 consecutive specimens drawn over at least an 18- to 24-month interval. There is variability. Longer time periods increase reliability but, as calculation of PSA velocity over longer prior time intervals usually decreases the PSA velocity estimate, they might decrease predictive power. It is also important to remember that biologic variability and/or prostatitis may be confounding factors in determining PSA velocity; therefore, antibiotic therapy and repeated PSA measurements may be considered to minimize these sources of confusion.

Percent free PSA in selected patients where risk of biopsy and/or diagnosis and treatment is outweighed by comorbid conditions

≤ 10\% \text{l} \rightarrow \text{Biopsy (see page 249)}

> 10 and ≤ 25\% \text{l} \rightarrow \text{Follow-up with DRE and total or percent free PSA (category 2B)}

> 25\% \text{l} \rightarrow \text{Annual follow-up with DRE, total PSA, and percent free PSA}

**To view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org.**

© Journal of the National Comprehensive Cancer Network | Volume 8 Number 2 | February 2010

© 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.
**Prostate Cancer Early Detection Version 2:2010**

**SCREENING RESULTS**

- **PSA > 10 ng/mL** → Biopsy
  - **Cancer** → See NCCN Prostate Cancer Guidelines*
  - **Atypia, suspicious for cancer or High-grade PIN** → See TRUS-guided biopsy (facing page)
  - **Benign** → Re-evaluate with PSA and DRE
    - **Timing interval 3-12 mo based on doctor-patient discussion**
  - **Repeat PSA and DRE in 6-12 mo**
  - **6-12 mo follow-up with DRE, total or percent free PSA, including PSA velocity:**
    - **c** Consider a third biopsy based on individual patient parameters and choice
  - **Positive** → See NCCN Prostate Cancer Guidelines*
  - **Negative** → Repeat PSA and DRE in 6-12 mo

**FOLLOW-UP**

- **Biopsy not done**

---

*To view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org.

---

**PSA velocity:** For men with PSA < 4 ng/mL, data suggest that a PSA velocity of ≥ 0.35 ng/mL per year is suspicious for the presence of cancer (Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521-1527); for men with PSA 4-10 ng/mL, a PSA velocity of ≥ 0.75 ng/mL/yr is suspicious for cancer. PSA velocity in men with PSA > 10 ng/mL has not been determined useful. Measurement should be made on at least 3 consecutive specimens drawn over at least an 18- to 24-month interval. There is variability. Longer time periods increase reliability but, as calculation of PSA velocity over longer prior time intervals usually decreases the PSA velocity estimate, they might decrease predictive power. It is also important to remember that biologic variability and/or prostatitis may be confounding factors in determining PSA velocity; therefore, antibiotic therapy and repeated PSA measurements may be considered to minimize these sources of confusion.
FOLLOW-UP FOR TRUS BIOPSIES

**TRUS-GUIDED BIOPSY**

- **Initial and Repeat**
  - Extended-pattern biopsy (12 cores)
    - **Number of Cores:**
      - Sextant (6) and,
      - Lateral peripheral zone (6) and,
      - Lesion-directed at palpable nodule or suspicious image
    - Transition zone biopsy is not supported in routine biopsy. However, the addition of a transition zone biopsy to an extended biopsy protocol may be considered in a repeat biopsy if PSA is persistently elevated.
    - After 2 negative extended TRUS biopsies, prostate cancer is not commonly found at repeat biopsy.
    - For high-risk men with multiple negative biopsies, consideration can be given to a saturation biopsy strategy.
    - Local anesthesia can decrease pain/discomfort associated with prostate biopsy.

- **If initial sextant biopsy used, rebiopsy using extended pattern**

- **If extended pattern used initially, immediate repeat biopsy is probably not necessary within the first year; consider delayed repeat biopsy using extended strategy**

- **Follow-up, based on DRE and PSA findings:**
  - Positive DRE (see page 245)
  - High-risk (see page 246)
  - PSA 4-10 (see page 247)
  - PSA > 10 (see facing page)

---

*To view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org.*

---
Prostate Cancer Early Detection Version 2:2010

SUGGESTED “TALKING POINTS” FOR DISCUSSION WITH A POTENTIAL SCREENEE ABOUT THE PROS AND CONS OF PSA TESTING

- Prostate cancer is the most common cancer found in older men, other than skin cancer.¹ Men in the United States have approximately a 1 in 6 chance of eventually finding out they have prostate cancer.² Men who have regular PSA tests have a higher chance of finding out they have prostate cancer, whereas those who do not have regular PSA tests have a lower chance but a higher probability of having more advanced cancer when ultimately diagnosed. The PSA test can detect most prostate cancers earlier than a DRE when no symptoms are present.

- African-American men and men with a father, brother, or son with prostate cancer (especially if it was found at a younger age) have a higher risk for developing prostate cancer. Native American and Asian-American men have a substantially lower risk.²

- American men also have approximately a 1 in 30 chance of eventually dying from prostate cancer. However, this would be higher if no men opted for early detection and treatment. Approximately 30,000 men die of prostate cancer each year in the United States. Only about 1 in 100 prostate cancer deaths occur in men younger than 55 years. Approximately 1 in 20 prostate cancer deaths occur in men aged 55-64 years, 2 in 10 in men aged 65-74 years, and 7 in 10 in men aged 75 and older.² However, these deaths usually occur after some period of metastatic disease.

- Many prostate cancers grow very slowly. Consequently, many men with prostate cancer may die of something else before their prostate cancer causes any symptoms. However, prostate cancers that grow more rapidly can potentially impact overall survival and quality of life. Whether a man will die of something else or prostate cancer depends on how aggressive the cancer is, how early it is detected, and how effectively it is treated, and the man's age and other medical problems. Most experts believe that in general men older than 75 years, or even younger men with serious medical problems, have little to gain from a PSA test.

- Doctors disagree about what level of PSA is high enough to perform further testing, such as a prostate biopsy, to look for prostate cancer. Most doctors feel men with PSA levels greater than 4 should have a biopsy, whereas others feel that men with levels greater than 2.5 should have a biopsy. There is an increasing tendency to focus less on absolute PSA values and to consider changes in PSA over time. Accumulating evidence shows that men who have a steady rise in their PSA level are more likely to have cancer, and if the rise is rapid, the cancer is more likely to be life-threatening. Other factors, such as patient age and prostate volume (how large the gland is), are also important to consider when deciding who needs a prostate biopsy.

- A prostate biopsy is usually performed using local anesthesia administered through a needle inserted into a probe placed into the rectum. This needle is used to take samples of the prostate tissue. Usually 10 to 12 samples are taken. The prostate biopsy, not the PSA test, tells whether a man has prostate cancer. A prostate biopsy is usually well tolerated and infrequently causes serious problems such as rectal or urinary hemorrhage, infection, or urinary retention.

- A PSA test can be abnormal even when a man does not have prostate cancer. This is called a “false-positive” test. These false-positive PSA tests can result from other prostate conditions that are not important to find (unless a man has bothersome urinary symptoms). Approximately 1 of 3 men with a high PSA level have prostate cancer, which means that 2 of 3 do not. The higher the PSA level, the more likely a man will be found to have prostate cancer if a biopsy is performed.³

- A PSA test can also be normal even when a man does have prostate cancer. This is called a “false-negative” test. Approximately 1 of 7 men with PSA levels less than 4 have prostate cancer, which means 6 of 7 do not.⁴ The higher a man’s PSA level is across all PSA ranges from zero on up, the more likely a man is to have prostate cancer. This is true even within the so-called “normal” range.⁴

- Prostate biopsies aren't perfect tests, either. Prostate biopsies sometimes miss cancer when present. Some doctors recommend a second set of biopsies if the first set is negative. Others will follow the PSA level and suggest more biopsies only if the level continues to rise.

SUGGESTED “TALKING POINTS” FOR DISCUSSION WITH A POTENTIAL SCREENEE ABOUT THE PROS AND CONS OF PSA TESTING (Cont.)

- If prostate cancer is found after a PSA test and a biopsy, common treatments are surgery to remove the prostate or radiation treatment to the prostate. Surgery has a very small risk for death. Both radiation and surgery can cause problems with urinary leakage in some men, but the risk for urinary leakage is higher with surgery. Both radiation and surgery cause problems with getting and keeping an erection in many men. The risk for problems with erections is higher with surgery in the short run, but over the long run, the risk is about the same with the 2 treatments.2 Radiation, however, is also associated with a risk for causing bowel problems in some men. Some men, especially older men with slower-growing cancers, may not need treatments such as surgery or radiation for their prostate cancer, and can be followed up with periodic PSA tests and physical examinations, a process known as “watchful waiting,” “active surveillance,” or “expectant management.”

- It is not clear if screening a man with the PSA test lowers his chances of eventually dying of prostate cancer or helps him live longer. It is also not clear if screening a man with the PSA test lowers a man’s chances of eventually having to deal with complications of prostate cancer, such as painful spread of prostate cancer to the bones, but the lower rates of advanced-stage disease at diagnosis and the lower rates of prostate cancer deaths suggest that fewer men may experience advanced disease. As a result, doctors disagree over the value of screening men with the PSA test. However, it is well established that screening has been associated with an unprecedented shift in the stages of prostate cancer at diagnosis. More than 75% of cancers are now detected when they are confined to the prostate gland, when current therapies are most effective. The actual relationship to PSA testing, however, remains unknown, but available evidence suggests that the lower mortality rates may be at least partly from PSA testing. Randomized trials are the best way to determine how PSA testing affects the death rate from prostate cancer.

- Level 1 evidence for PSA screening is now available through a European study released in 2009. The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in the early 1990s to evaluate the effect of PSA testing on death rates from prostate cancer. The trial involved 182,000 men between the ages of 50 and 74 years in 7 European countries, randomly assigned to a group that was offered PSA screening at an average of once every 4 years or to a control group that did not receive such screening. The predefined core group included 162,243 men of ages of 55-69 years. Death from prostate cancer was the primary outcome. During a median follow-up of 9 years, the cumulative incidence of prostate cancer was 8.2% in the screening group and 4.8% in the control group. There were 214 prostate cancer deaths in the screening group, and 326 in the control group. The rate ratio for death from prostate cancer in the screening group, compared to the control group, was 0.80 (95% CI, 0.65-0.98; adjusted P = .04). The researchers concluded that PSA-based screening reduced the rate of death from prostate cancer by 20%. However, they also concluded that this was associated with a high risk for overdiagnosis. Statistically, 1410 men would need to be screened and 48 men would need to be treated to prevent 1 death from prostate cancer.6

- In summary, there are advantages and disadvantages to having a PSA test, and there is no “right” answer about PSA testing for everyone. Each man should make an informed decision about whether the PSA test is right for him.

- Frequency of biopsy complications with 10 core biopsy:
  - Hematospermia: 37.4%
  - Hematuria > 1 day: 14.5%
  - Rectal bleeding < 2 days: 2.2%
  - Prostatitis: 1.0%
  - Fever > 38.5°C (101.3°F): 0.8%
  - Epididymitis: 0.7%
  - Rectal bleeding > 2 days + requiring surgical intervention: 0.7%
  - Urinary retention: 0.2%
  - Other complications requiring hospitalization: 0.3%

men with prostate cancer will not die of this disease, treatment (often with significant side effects) is unnecessary for some patients. However, prostate cancer remains the second most common cause of male cancer deaths. Mortality related to prostate cancer depends on how aggressive the cancer is and the patient’s age and comorbidities. Most experts believe that men older than 75 years have little to gain from PSA testing, unless they have an aggressive tumor, in which case they may have substantial benefits. Unfortunately, no reliable method exists to distinguish between aggressive and slow-growing tumors.

Many would agree that the introduction of early detection methods such as digital rectal examination (DRE) and the serum PSA test has played a critical role in the downward migration of prostate cancer stage seen over the past decade. The rate of metastatic disease seen at diagnosis has substantially decreased since 1988.7,8 Currently, 70% to 80% of prostate cancers are pathologically organ-confined at diagnosis.9 Studies have shown that prostate cancer cases detected through PSA screening are more often confined to the prostate than those detected solely by DRE.10,11

Two large randomized trials initiated in the early 1990s have recently reported the impact of PSA screening on health outcome: the PLCO (Prostate, Lung, Colorectal, and Ovary) in the United States and the ERSPC (European Randomized Screening for Prostate Cancer) in Europe. Interim reports were released in 2009.12,13 The ERSPC13 involved 182,000 men between ages 50 and 74 years in 7 European countries randomly assigned to a group that was offered PSA screening at an average of once every 4 years or to a control group that did not receive this screening. An estimated 20% “contamination” (use of PSA tests) occurred in the control group. The predefined core group included 162,243 men aged 55 to 69 years. Death from prostate cancer was the primary outcome. During a median follow-up of 9 years, the cumulative incidence of prostate cancer was 8.2% in the screening group versus 4.8% in the control group. There were 214 prostate cancer deaths in the screening group compared with 326 in the control. The rate ratio for death from prostate cancer was 0.80 when comparing the screening arm with the control arm (95% CI, 0.65–0.98; P = .04). The investigators concluded that the PSA-based screening program reduced mortality from prostate cancer by 20%. However, they also noted that this was associated with a high risk for overdiagnosis. Statistically, 1410 men would need to be screened and 48 additional men treated to prevent one death from this malignancy. The NCCN panel considers this report high-level evidence, although the follow-up time is relatively short for definitive conclusions. Future updates on this trial will provide more information.

The PLCO study12 randomized 76,693 men at 10 United States study centers to either annual screening (annual PSA for 6 years and DRE for 4 years) or usual care. After 7 years of follow-up, the incidence rate ratio was 1.22 for the screening arm compared with the control arm (95% CI, 1.16–1.29). The investigators did not find a statistically significant difference between the mortality rates of the screening (50 deaths; 2.0 per 10,000) and control groups (44 deaths; 1.7 per 10,000). Despite the impressive sample size, the report is heavily flawed by the short follow-up time and the unusually high contamination rate of 40% to 52% in the control group. Improvement in mortality resulting from PSA testing is likely a long-term outcome evident only with longer follow-up.

In light of these results, panelists raised several points. First, the ERSPC study outlined a beneficial but not necessarily exclusive scheme in using PSA testing to prevent deaths from prostate cancer (testing men between ages 50–74 every 4 years). Second, PSA testing is likely optimal when used for early detection in high-risk populations instead of general screening. Focusing on rigorous early detection in young men of African descent or with a strong family history of prostate cancer (first-degree relative with prostate cancer, especially at a young age) may be the key to improving the survival rate of this malignancy. Unfortunately, neither study addressed high-risk factors, with fewer than 5% of PLCO participants of African-American descent and only 7% with a reported family history.12 Third, panelists agreed that age is an important factor for consideration. Young men in a high-risk group have a heightened chance of dying of prostate cancer and will thus benefit from early testing. For older men, more judicious use and interpretation of the PSA test is warranted to prevent overdiagnosis.

**PSA Test and its Derivatives**

When the first recommendations for early detection programs for prostate cancer were made, serum total
PSA (tPSA) was the only PSA-based test available. Subsequent years have seen the development of an exciting series of PSA derivatives that are possibly useful in increasing specificity and decreasing unnecessary biopsies.

PSA Velocity: The development of PSA testing is arguably the most important advance that has been made in detecting prostate cancer at an early stage. PSA is a glycoprotein secreted by prostatic epithelial cells, and its protease activity lyses the clotted ejaculate to enhance sperm motility. Although primarily confined to the seminal plasma, PSA leaks into the circulation through an unknown mechanism. Many commercially available sources of PSA antibodies for serum tests are now available worldwide. Except for minor differences in the calibration of these assays, they perform comparably when used appropriately. However, the levels are not interchangeable because they are standardized against 2 different standards. The test should be repeated if increased levels are noted, particularly if the value is close to the threshold.

Effect of Medication and Herbal Supplements on PSA Velocity: The effect of the 5-alpha reductase inhibitors finasteride and dutasteride on serum PSA levels has been well documented in several studies. This class of drugs typically results in an approximate 50% decrease in serum PSA levels after 6 to 12 months. However, this effect is tremendously variable. For example, one study showed that at 1 year, only 35% of men had the expected 40% to 60% decrease in PSA and another 30% had greater than a 60% decrease in serum PSA levels. Thus, not only should care be taken to elicit the use and duration of 5-alpha reductase inhibitors during history taking but also the commonly used “rule of thumb” to simply double the measured PSA value may result in unreliable cancer detection.

A health survey of 12,457 men visiting a prostate cancer screening clinic showed that more than 20% took herbal supplements, whereas only 10% took prescription medication (e.g., finasteride) for lower urinary tract symptoms. Several of these herbal supplements, such as saw palmetto, may contain phytoestrogenic compounds that can affect serum PSA levels. Little is known about the exact composition of these herbal supplements and their specific effects on serum PSA levels.

PSA Thresholds: Numerous studies have shown that a PSA level above 4 ng/mL increases the chance of detecting prostate cancer at biopsy 30% to 35%. Large programs for the early detection of prostate cancer have shown that nearly 70% of cancer cases can be detected using a PSA cutoff level of 4 ng/mL in the first 4 years. Overall, appropriate use of PSA alone can provide a diagnostic lead time of nearly 5 to 10 years compared with DRE. More than 90% of PSA-detected cancers are biologically significant based on tumor volume and grade criteria. PSA examination results in detection of earlier, organ-confined disease. Recent studies have investigated the predictive value of evaluating men with PSA values within the 2.5 to 4.0 ng/mL range (see subsequent sections).

PSA Velocity: The rate of change in PSA over time is called the PSA velocity (PSAV) and was first introduced by Carter et al. This study showed for the first time that the “rate of change” of serum PSA over time provides useful information and increases the specificity of PSA for cancer detection. These authors showed that a cutoff of 0.75 ng/mL per year had a sensitivity of 79% among men with cancer and a specificity of approximately 90% among those without cancer when PSA levels were between 4 and 10 ng/mL. When PSA levels were less than 4 ng/mL, sensitivity using a cutoff of 0.75 ng/mL was only 11%, but more recent studies from the same group showed that a PSAV of more than 0.35 ng/mL per year and a high risk count (i.e., number of times the PSAV exceeds a threshold) 10 to 20 years before diagnosis predict high-risk prostate cancer. Among men with prostate cancer, a high PSAV (> 2 ng/mL/y) during the year before diagnosis is also associated with an increased risk for death from the disease. The predictive value of PSAV can be influenced by other factors, such as absolute PSA level.
Age-specific PSA reference ranges were introduced as a way to increase cancer detection (increase sensitivity) in younger men through lowering their PSA cutoff values, and decreasing unnecessary biopsies (improve specificity) in older men through increasing their PSA cutoffs. These age-specific ranges have been investigated by several groups with equivocal results. Race-specific reference ranges have also been suggested. However, the exact roles of these age- and race-specific PSA cutoffs in the early detection of prostate cancer remain unclear and continue to be the source of debate. The panel, therefore, chose not to incorporate these variables into the current guidelines.

**Percent Free PSA:** A flurry of exciting work over the past decade has characterized a family of molecular forms of PSA and their possible clinical roles. Free (unbound) PSA (fPSA) expressed as a ratio of total PSA has emerged as a clinically useful molecular form of PSA with the potential to provide improvements in early detection, staging, and monitoring of prostate cancer. Several molecular forms of PSA are known to circulate in the blood. In most men, most (60%–90%) circulating PSA is covalently bound to endogenous protease inhibitors, and most immunoreactive PSA is bound to a protease inhibitor called alpha-1-antichymotrypsin. Other immunoreactive PSA–protease inhibitor complexes, such as alpha-1-antitrypsin and protease C inhibitor, exist at serum concentrations so low that their clinical significance has not been determined. In addition, a large proportion of PSA is complexed with alpha-2-macroglobulin. Unfortunately, this PSA–alpha-2-macroglobulin complex cannot be measured with conventional assays because of the shielding (or “caging”) of PSA antigenic epitopes by alpha-2-macroglobulin.

Most clinical work investigating the use of the molecular forms of PSA for early detection of prostate cancer has focused on the percentage of PSA found circulating in the free or unbound form (fPSA). Numerous studies have shown that the percentage of fPSA is significantly lower in men who have prostate cancer than in those who do not.

The FDA approved the use of percent fPSA for the early detection of prostate cancer in men with PSA levels between 4 and 10 ng/mL. The multi-institutional study that characterized the clinical usefulness of this assay showed that a 25% fPSA cutoff detected 95% of prostate cancers while avoiding 20% of unnecessary prostate biopsies. Since its approval by the FDA, testing for percent fPSA has gained widespread clinical acceptance in the United States, specifically for patients with normal DREs who have previously undergone prostate biopsy because they had a PSA level within the “diagnostic gray zone” (i.e., 4–10 ng/mL).

**Complexed PSA:** PSA exists in free and several complexed forms. Direct measurement of the complexed form (cPSA) with alpha-1-antichymotrypsin is now available. For practical purposes, tPSA consists essentially of fPSA and the alpha-1-antichymotrypsin complexed form. The threshold levels are therefore not equivalent: cPSA levels of 2.2 and 3.4 ng/mL are equivalent to tPSA levels of 2.5 and 4.0 ng/mL, respectively. In a multicenter trial of 831 men, of whom 313 had prostate cancer, researchers found that cPSA ranging from 80% to 95% sensitivity thresholds increased specificity compared with tPSA. Results were similar for percent cPSA and percent fPSA. Therefore, the ratio of cPSA to tPSA should provide information comparable to the fPSA-to-tPSA ratio.

Other studies also showed an enhanced specificity of cPSA within certain tPSA ranges. Use of cPSA has been approved as an aid in the detection of prostate cancer in men aged 50 years or older in conjunction with DRE. However, because cPSA has not gained widespread acceptance in the United States, specifically for patients with normal DREs who have previously undergone prostate biopsy, the use of cPSA remains controversial.

**PSA Density:** PSA density (PSAD) requires the measurement of prostate volume through transrectal ultrasound (TRUS) and is expressed as the PSA value (in ng/mL) divided by the prostate volume (in cm³). Benson et al. first proposed the use of PSAD as a way to discriminate prostate cancer from the most frequent cause of PSA elevation, benign prostatic hypertrophy. Initially, PSAD was used to differentiate high PSA levels in men with large prostates who did not have prostate cancer. A PSAD cutoff of 0.15 mg/mL/cm³ was recommended in earlier studies, which spared as many as 50% of these patients from undergoing unnecessary biopsies. However, some subsequent studies have reported that this cutoff has insufficient sensitivity.

More recent studies have tried to improve on the performance of PSAD by using cPSA or fPSA.

© Journal of the National Comprehensive Cancer Network | Volume 8 Number 2 | February 2010
in the numerator or correcting the denominator for transition zone volume.\(^{46}\) The lack of measurement precision of both PSA and prostate volume has prevented the widespread clinical acceptance of PSAD. In addition, studies have shown that percent fPSA provides comparable results to PSAD in early-detection algorithms.\(^{41}\) Although the panel recognizes that PSAD may explain an elevated PSA value considered after negative biopsies, it is not incorporated into these guidelines because it offers little added benefit over other tests. However, PSAD has been clinically underused and may be considered in evaluating patients, especially those who have had prior ultrasound-determined measurements of prostate volume. PSAD has been shown to correlate with prostate cancer presence and aggressiveness, and can predict adverse pathology and biochemical progression after treatment.\(^{42,43}\)

**Age at Onset of Screening:** Although 50 years has traditionally been the age to start considering PSA screening, researchers have recognized that high-risk groups, such as African-Americans and men with family histories of prostate cancer, may benefit from beginning screening at an earlier age.

The Baltimore Longitudinal Study on Aging identified median PSA levels as a function of age, with a median PSA of 0.6 ng/mL for men in their 40s and 0.7 ng/mL for those in their 50s. Significantly, this study found a threefold higher risk for prostate cancer within 10 to 25 years if PSA was greater than the median for the patient's age group.\(^{44}\) For patients screened in their 50s, a baseline PSA value between the age-specific median and 2.5 ng/mL was associated with a 7.6-fold higher risk for prostate cancer.\(^{45}\) Autopsy studies have shown that histologic evidence of prostate cancer is present in approximately 25% of men in the fourth decade of life, and the Surveillance Epidemiology and End Results (SEER) database shows that prostate cancer deaths begin to appear in men in their 40s.\(^{4}\) Accordingly, to prevent these tragic, untimely deaths, screening for prostate cancer should begin earlier. In addition, PSA values of men in their 40s are less influenced by the possible presence of significant benign prostatic hyperplasia. Obtaining a baseline PSA test at 40 years of age to assess the risk for subsequent prostate cancer detection seems reasonable. This risk assessment might be useful in determining the most appropriate surveillance strategy for the individual, and whether or when a prostate biopsy should be recommended. However, several panelists also expressed doubts about the cost-effectiveness and concerns on potential overdiagnosis of universal testing at age 40. Nonetheless, there is uniform agreement that an early screening program will likely benefit young men in a predefined high-risk group (African descent, family history).

**Threshold for Prostatic Biopsy:** A total PSA level of 4.0 ng/mL has traditionally been used as the threshold for considering a prostate biopsy, recognizing that 30% to 35% of men with levels in the 4.0 to 10.0 ng/mL range will be found to have cancer. Subsequent studies have shown that a substantial number of men with a PSA level between 2.5 and 4.0 ng/mL will have cancer. A study of 332 screened men with PSA levels in this range showed a 22% incidence of prostate cancer through biopsy.\(^{46}\) A prospective study of 151 subjects with PSA values in this range showed an incidence of 24.5%.\(^{47}\) These cancers are comparable to those found with higher PSA levels in terms of clinical significance based on the volume and Gleason score, but are more frequently organ-confined.\(^{48,49}\) Researchers have estimated that lowering the threshold to 2.6 ng/mL would double the rate of detecting cancer in men younger than 60 years with little loss of specificity.\(^{50}\)

The Prostate Cancer Prevention Trial (PCPT) showed that 15% of men with a PSA level of 4.0 ng/mL or less and a normal DRE had prostate cancer diagnosed on end-of-study biopsies.\(^{51}\) A direct correlation was seen between the PSA level and the prostate cancer detection rate, ranging up to 26.9% in patients whose PSA was 3.1 to 4.0 ng/mL. High-grade prostate cancers (defined by a Gleason score ≥ 7) were prevalent in 25% of patients with PSA levels of 3.1 to 4.0 ng/mL. Thus, high-grade prostate cancers detected through biopsy are not rare among men with PSA levels of 4.0 ng/mL or less.

Based on this finding and other supportive data, it now appears that using a PSA threshold of 4.0 ng/mL will miss a significant number of potentially curable tumors. The NCCN guidelines therefore recommend considering biopsies for men with PSA levels in the range of 2.6 to 4.0 ng/mL. The caveat remains, of course, that showing definitive improvement in mortality from PSA screening still awaits the results of ongoing, large, randomized trials and considerations of quality of life.
NCCN Guidelines

General Considerations

The decision to participate in an early detection program for prostate cancer is complex for patients and physicians. Important factors that must be considered when beginning an early detection program include patient age, life expectancy, family history, race, and previous early detection test results. Most importantly, patients and physicians must understand the risks and benefits associated with the early detection and treatment of prostate cancer. Several general principles for early detection should be clearly understood before using the NCCN guidelines:

- No portion of these early detection guidelines is designed to replace an accurate history and complete physical examination conducted by a physician.
- The general health, medical comorbidities, and life expectancy of the patient are paramount when recommending or designing an early detection program.
- Prostate cancer risk factors, such as family history and race (i.e., African-American), must be considered before deciding to initiate an early detection program.
- Prostate cancer in its early stages has no identifiable symptoms. In advanced disease, symptoms may include urinary obstruction, prostatic bleeding, hematospermia, and bone pain. Although most men wishing to participate in early detection programs have no symptoms of prostate cancer, they may have mild to severe symptoms of lower urinary tract disease because of benign prostatic enlargement. Care should be taken to educate patients about the distinction between these 2 diseases when discussing the risks and benefits associated with early detection.
- A patient’s history of prior testing, including DRE, PSA, PSA derivatives, and prostate biopsy, must be considered when designing an early detection program. Patients who have had numerous serial PSA values should make the information available to their physicians. In addition, previous negative prostate biopsy results and the actual histologic findings should also be made available. Although a clear understanding of the approach to early detection in men who have a long history of abnormal PSA values has not been completely documented, these earlier test results should be considered when testing intervals are chosen.
- Numerous large, community-based early detection programs have clearly documented the synergy of DRE and PSA testing in increasing the sensitivity for the detection of prostate cancer over the use of either test alone. Serum PSA testing is not a substitute for a thorough DRE.
- tPSA levels greater than 10 ng/mL confer a greater than 67% likelihood of harboring prostate cancer. Thus, men with serum PSA values over this level (regardless of their DRE results, percent fPSA, or PSAV values) should undergo a TRUS-guided biopsy of the prostate. False-negative findings should be discussed clearly with patients and a repeat biopsy considered if tPSA values continue to remain in the high-risk category.

Specific Considerations

Physicians and potential participants must thoroughly discuss the pros and cons of screening (see pages 250 and 251).

Studies have shown that among the general population of men in their 40s, baseline PSA level is predictive of prostate cancer diagnosis many years later.45,52 Hence, for men opting to participate in an early detection program, baseline DRE and PSA testing at age 40 years is useful. Annual follow-up is recommended for men who have a PSA value 1.0 ng/mL or greater. Men with PSA levels below 1.0 ng/mL should be screened again at 45 years of age. These recommendations have a majority, but not uniform, panel consensus for men of average risk (category 2B). Regular screening should be offered to all participants starting at age 50 years.

Men of African-American descent and those with a first-degree relative diagnosed with prostate cancer (especially at a young age) have a significantly higher risk.2–4 For these men, panelists agreed that earlier (start in the 40s) and more frequent screening is appropriate. Panelists also agree that screening and biopsy decisions should be individualized for men older than 75 years; less-frequent PSA/DRE may be reasonable. This determination is supported by a recent longitudinal study of 849 men that found no prostate cancer deaths among men aged 75 to 80 years with PSA levels below 3.0 ng/mL.53

Prostate Biopsy

Initial Biopsy: Systematic prostate biopsy with
TRUS guidance is the recommended technique for prostate biopsy. Initially described as a sextant technique sampling both right and left sides from the apex, mid-gland, and base in the mid-parasagittal plane, more recently extended biopsy schemes have shown improved cancer detection rates. Although no one scheme is considered optimal for all prostate shapes and sizes, most emphasize better sampling of the lateral aspect of the peripheral zone. One commonly used scheme is the 12-core biopsy scheme that includes a standard sextant and a lateral sextant scheme (lateral apex, lateral mid-gland, lateral base). This scheme has been validated in a large study of 2299 patients involving 167 community-based urologists. The overall cancer detection rate in this referral-based population was 44%. If only a sextant scheme was performed, approximately 20% of the cancers in the series would have been missed. Lesion-directed biopsies (hyperechoic lesions seen on TRUS) rarely contribute to unique cancer identification not detected by extended systematic biopsy. Transition zone biopsies performed as an initial biopsy have low efficacy and are not recommended.

The panel recommends an extended-pattern 12-core biopsy (sextant [6] and lateral peripheral zone [6] and lesion-directed palpable nodule or suspicious image). Transition zone biopsy is not supported in routine biopsy. However, this can be added to an extended biopsy protocol in a repeat biopsy if PSA is persistently elevated.

**Repeat Biopsy Technique:** Patients with prior negative biopsies, yet persistently rising PSA values should undergo repeat biopsy. Important factors in predicting chance of cancer on repeat biopsy include PSAV and the adequacy of initial biopsy (number of cores, prostate size). Cancer detection rates are higher in men with prior negative sextant biopsies than in those with prior negative extended biopsies. Yields are highest in the laterally directed and apical cores. Particular attention should be given to apical sampling, including the anterior apical horn, which is comprised of peripheral zone. Transition zone biopsies can be considered in patients undergoing repeat biopsy. In patients with 2 negative extended biopsies but persistently rising PSA values, a saturation biopsy may be considered.

**Use of Anesthesia:** Historically, up to 90% of men undergoing a prostate biopsy have reported some discomfort during the procedure. Both topical lidocaine gel and an injectable nerve block have been shown to be safe and efficacious in reducing discomfort. Topical lidocaine was more efficacious in reducing pain during probe insertion, whereas periprostatic injection reduced pain during the biopsy itself. These minor anesthetic techniques greatly enhance the acceptability of the procedure, particularly with extended templates and saturation techniques, but should be considered in all patients. For exceptional cases, such as men with anal strictures or patients who have been inadequately blocked with a periprostatic injection, intravenous sedation or general anesthetic may be advantageous.

**Percent fPSA:** The NCCN guidelines recommend using percent fPSA as an alternative in the management of patients with normal DREs and tPSA levels between 4 and 10 ng/mL if they have a contraindication to biopsy. Physicians and patients electing to use percent fPSA should be cautioned that this assay and the multi-institution study performed to obtain its FDA approval were designed with the intention of avoiding unnecessary biopsies in men with a high likelihood of not having prostate cancer. If an anticoagulated patient presents with a negative DRE, tPSA value of 4 to 10 ng/mL, and percent fPSA levels greater than 25%, annual follow-up with DRE, tPSA, and percent fPSA can be considered. This strategy met with less consensus (category 2B) for patients whose percent fPSA is greater than 10% and 25% or less, in which case biopsy is preferred.

Percent fPSA levels less than 10% are clearly associated with a high risk for having prostate cancer, and patients should be encouraged to undergo a biopsy if percent fPSA values fall below this level. A negative linear relationship exists between the likelihood of having prostate cancer and percent fPSA values between the levels of 10% and 25%. The risks associated with these values should be carefully discussed with the patient before electing to forego prostate biopsy. In general, percent fPSA is used in the decision process when an individual has had an initial negative biopsy.

In addition, physicians should consult the clinical chemistry laboratory to determine manufacturer’s recommendations regarding sample collection and handling. Also, “mixing and matching” fPSA and tPSA assays from different manufacturers is not recommended and may lead to spurious results.

**PSAV:** Initial studies of PSAV have determined that
an increase in the serum PSA levels 0.5 ng/mL per year or greater indicates a high likelihood of having prostate cancer. A study of 980 men by Carter et al. suggested that a PSAV of greater than or equal to 0.35 ng/mL per year is suspicious of cancer and biopsy is recommended. However, the small number of deaths from prostate cancer (20) in the study precludes definitive conclusions. Whether a velocity of 0.35 ng/mL per year is a reliable criterion for recommending biopsy when the PSA level is low is a matter of debate.

Carter et al. also described the technique for calculating PSAV in detail. The PSA values used to calculate PSAV should be performed using similar assay techniques in the same clinical laboratory. PSAV should be calculated from at least 3 consecutive PSA values obtained over at least an 18- to 24-month period. Longer periods increase reliability. In patients using finasteride or dutasteride, failure to have a substantial decrease in PSA or an increase indicates that they are at increased risk for prostate cancer.

The research that went into the determination of PSAV cutoff points was collected primarily in men with PSA levels less than or equal to 10 ng/mL. A recent screening study reported that PSAV is not useful for cancer detection or prognostic prediction for men with PSA levels greater than 10 ng/mL. However, guideline panel members universally endorse performing a prostate biopsy in all men with a PSA value greater than 10 ng/mL who also fulfill other screening criteria. Patients and physicians electing to monitor prostate disease through measuring PSAV should be cautioned that fluctuations between measurements can occur as a result of either laboratory variability related to interassay variability from the use of different commercially available sources or from individual biologic variability. Prostatitis may also cause PSAV to rise. Antibiotic therapy and repeated measurements may be considered to minimize these confounding factors.

Management of Negative or Suspicious Biopsies:
Increasingly, pathologists have recognized the importance of reporting nonmalignant but pathologically atypical findings. High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation are noted in up to 14% and 3% of biopsies, respectively. These diagnoses are often confirmed through the use of immunohistochemical staining for basal cell markers and markers of neoplasia such as Alpha Methyl-Acyl CoA Racemase (AMACR),

High-Grade Prostatic Intraepithelial Neoplasia:
Cytologically, the nuclear features of high-grade prostatic intraepithelial neoplasia (HGPIN) resemble that of cancer; however, the presence of a basal layer on the acini distinguishes this entity from cancer. Extended biopsy schemes have dramatically resulted in a decline in the positive biopsy rate in patients initially found to have HGPIN. Although reports in the sextant biopsy scheme era showed positive biopsy rates of approximately 50%, contemporary series using extended biopsy schemes report positive biopsy rates of approximately 10% to 20%.

Atypia, Suspicious for Cancer:
Distinct from HGPIN, in which a basal cell layer is present, atypia is characterized by small single-cell layer acini. However, because so few glands are present on the biopsy specimen, an unequivocal diagnosis of cancer cannot be established. Even in the era of extended biopsy schemes, positive biopsy rates in patients with atypia are 50% or more and the most likely area of finding cancer resides in the prostate area showing atypia. Hence, a repeat extended biopsy scheme is warranted, with additional cores obtained from the prior region showing atypia.

If the biopsy result for a man with PSA level greater than 10 ng/mL shows histologic evidence of atypia or HGPIN, TRUS-guided biopsy is indicated. The NCCN guidelines therefore recommend that if HGPIN is found on TRUS-guided biopsy of less than 10 cores, repeat biopsy using an extended pattern, including transition zone, is indicated if an extended biopsy strategy was not used. If extended biopsies were used, a delayed strategy (1 year after the extended biopsy) may be considered, as suggested by Lefkowitz et al. For findings of atypia suspicious for cancer, extended pattern biopsy (within 3 months) with increased sampling of the atypia site and adjacent areas is recommended.

Negative Biopsy in the Absence of Suspicious Lesions:
Men with a PSA of 4 to 10 ng/mL with a percent fPSA level less than or equal to 10% should undergo a repeat biopsy. If the fPSA level is greater than 10% and less than or equal to 25%, repeat biopsy or close follow-up with tPSA or percent fPSA (category 2B) can be considered. If the fPSA is greater than 25%, the surveillance strategy (6–12 month follow-up with DRE, tPSA, and percent fPSA) can be used.
If biopsy results are negative in a man with a serum PSA level greater than 10 ng/mL, DRE and PSA testing should be repeated, and a repeat prostate biopsy should be considered at a 3- to 12-month interval based on discussion with the patient. Given the importance of technique, issues discussed earlier regarding the use of extended or saturation techniques for a repeat prostate biopsy should be considered.

Summary
Since the early 1990s, many variants of the tPSA assay have been introduced to increase the sensitivity of screening programs (cancer detection) while maintaining specificity (elimination of unnecessary biopsies). Again, these guidelines recommend ways that individuals and their physicians can use these new techniques rationally for early detection of prostate cancer. These guidelines are not designed to provide an argument for using population screening programs for prostate cancer, but are meant to provide a vehicle for practicing early detection efforts in an evidence-based, systematic fashion in patients who choose to participate in these programs. Whether to treat a patient on diagnosis is beyond the scope of these guidelines (see NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer [in this issue; to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org]).

These guidelines incorporate many new validated findings in addition to the DRE and tPSA test, including percent fPSA, PSAV, cPSA, biopsy pathology, and TRUS-guided biopsy techniques. The panel will re-examine the clinical efficacy of these new modalities annually, and the guidelines will be modified accordingly. In addition, future iterations of these guidelines may incorporate new serum markers currently undergoing clinical investigation.

The goal of the NCCN and this guideline panel in updating these algorithms is to help men and clinicians choose a program for early detection of prostate cancer and make decisions about the need for prostate biopsy. Any clinician who uses these guidelines is expected to exercise independent medical judgment in the context of the individual clinical circumstances to determine each patient’s need for prostate biopsy. These guidelines will continue to evolve as the field of prostate cancer advances.

References
Prostate Cancer Early Detection


24. Eggener SE, Roehl KA, Catalona WJ. Prostatitis confounds the use of PSA velocity for prostate cancer detection [abstract]. Presented at the 2006 ASCO Prostate Cancer Symposium; February 24–26, 2006; San Francisco, California.


42. Allan RW, Sanderson H, Epstein JL. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol 2003;170:370–372.


## Individual Disclosures for the NCCN Prostate Cancer Early Detection Panel

<table>
<thead>
<tr>
<th>Panel Member</th>
<th>Clinical Research Support</th>
<th>Advisory Boards, Speakers Bureau, Expert Witness, or Consultant</th>
<th>Patent, Equity, or Royalty</th>
<th>Other</th>
<th>Date Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert R. Bahnson, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>7/6/09</td>
</tr>
<tr>
<td>Michael Barry, MD</td>
<td>National Cancer Institute; Foundation for Informed Medical Decision Making (a not-for-profit); NIH/NIA; and NIH/NIDDK</td>
<td>None</td>
<td>None</td>
<td>Foundation for Informed Medical Decision Making (a not-for-profit)</td>
<td>7/3/09</td>
</tr>
<tr>
<td>J. Erik Busby, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>7/6/09</td>
</tr>
<tr>
<td>Peter R. Carroll, MD</td>
<td>Abbott Laboratories; and National Cancer Institute</td>
<td>Myriad Genetic Laboratories, Inc.; Takeda Pharmaceuticals North America, Inc.; and Varian Medical Systems, Inc.</td>
<td>None</td>
<td>None</td>
<td>12/16/09</td>
</tr>
<tr>
<td>H. Ballentine Carter, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>9/29/09</td>
</tr>
<tr>
<td>William J. Catalona, MD</td>
<td>GlaxoSmithKline; Beckman-Coulter, Incorporated; and deCODE genetics, Inc</td>
<td>GlaxoSmithKline; Beckman Coulter Inc; and deCODE genetics</td>
<td>None</td>
<td>None</td>
<td>7/7/09</td>
</tr>
<tr>
<td>Michael S. Cookson, MD</td>
<td>Amgen Inc.; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Ferring; GTX; Indevus; sanofi-aventis U.S.; and Watson Pharmaceuticals, Inc.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>7/1/09</td>
</tr>
<tr>
<td>Jonathan I. Epstein, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>12/7/09</td>
</tr>
<tr>
<td>Ruth B. Etzioni, PhD</td>
<td>NIH</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>12/1/09</td>
</tr>
<tr>
<td>Veda N. Giri, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>9/30/09</td>
</tr>
<tr>
<td>George P. Hemstreet III, MD, PhD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>10/5/09</td>
</tr>
<tr>
<td>Richard J. Howe, PhD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>6/1/09</td>
</tr>
<tr>
<td>Mark H. Kawachi, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>10/16/09</td>
</tr>
<tr>
<td>Paul H. Lange, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>7/1/09</td>
</tr>
<tr>
<td>Hans Lilja, MD</td>
<td>National Cancer Institute; and IRIS, International, Inc.</td>
<td>None</td>
<td>Arctic Partners (Free PSA patent)</td>
<td>None</td>
<td>10/30/09</td>
</tr>
<tr>
<td>Kevin R. Loughlin, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>12/3/09</td>
</tr>
<tr>
<td>James Mohler, MD</td>
<td>Roswell Park Cancer Institute</td>
<td>None</td>
<td>None</td>
<td>Androbiosys, Inc.</td>
<td>8/18/09</td>
</tr>
<tr>
<td>Judd Moul, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>10/2/09</td>
</tr>
<tr>
<td>Robert B. Nadler, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>12/4/09</td>
</tr>
<tr>
<td>Stephen G Patterson, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>12/7/09</td>
</tr>
<tr>
<td>Joseph C. Presti, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>10/1/09</td>
</tr>
<tr>
<td>Antoinette M. Stroup, PhD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>9/28/09</td>
</tr>
<tr>
<td>Robert Wake, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>7/9/09</td>
</tr>
<tr>
<td>John T. Wei, MD, MS</td>
<td>envisionering Inc</td>
<td>envisionering Inc.; and genprobe</td>
<td>None</td>
<td>None</td>
<td>10/7/09</td>
</tr>
</tbody>
</table>

The NCCN guidelines staff have no conflicts to disclose.